info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Esophageal Squamous Cell Carcinoma Market Size

ID: MRFR//10527-CR | 128 Pages | Author: Kinjoll Dey| August 2023

Esophageal Squamous Cell Carcinoma Market to reach USD 1.45 billion by 2032 at 8.16% CAGR. Market dynamics depend on Esophageal Squamous Cell Carcinoma prevalence and incidence. ESCC is more common in Asia, Africa, and South America. These variances affect diagnostic and treatment demand, prompting region-specific techniques and medicines. Improved early detection and screening programs also help with late-stage diagnoses.

ESCC market dynamics depend on diagnostic advances. Imaging, endoscopic, and biomarker innovations aid early and accurate diagnosis. Early detection is crucial for better treatment outcomes, increasing diagnostic tool demand and novel method research. The necessity for non-invasive, sensitive, and specific approaches to detect ESCC at various stages drives market dynamics as diagnostic technologies evolve.

ESCC market dynamics depend on ongoing R&D. Pharmaceutical corporations, research institutions, and biotech enterprises investigate new therapeutic targets, biomarkers, and treatments. Precision medicine and tailored treatment techniques improve when more effective and focused medicines are developed and the molecular and genetic foundation of ESCC is more understood. Research and cooperation affect market dynamics and new therapy availability.

Precision medicine and cancer care changes affect the ESCC market. Genotyping, molecular profiling, and mutation discovery help develop targeted medicines. ESCC patients' treatment options are affected by personalized medicine, which tailors medicines to tumor genetics. New therapy paradigms, particularly immunotherapies, reflect oncology trends and impact the ESCC market.

ESCC market dynamics depend on regulation. The approval and regulatory processes for new medications, diagnostics, and therapies affect their availability and adoption. Regulatory bodies ensure the safety and efficacy of novel therapies, affecting timeframes and commercialization plans. Market entry requires regulatory compliance, and enterprises proactively traverse these concerns to affect ESCC market dynamics.

Collaboration between healthcare experts, advocacy groups, and government agencies affects the ESCC market. Awareness campaigns, screening programs, and early detection measures improve patient outcomes and market dynamics. Researchers, doctors, and patient advocacy groups collaborate to develop holistic ESCC prevention, diagnosis, and treatment solutions.

Covered Aspects:

Report Attribute/Metric Details
Growth Rate 8.16% (2023-2032)

Global Esophageal Squamous Cell Carcinoma Market Overview


The Esophageal Squamous Cell Carcinoma Market size was valued at USD 0.77 billion in 2022 and is projected to grow from USD 1.25 Billion in 2023 to USD 1.45 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.16% during the forecast period (2023 - 2032). The growing increasing prevalence of Achalasia, increased research activities & product approvals, and rising public awareness are driving market growth.


Esophageal Squamous Cell Carcinoma Market


Source: Secondary Research, Primary Research, MRFR Database and Analyst Review


In May 2024, Glenmark Specialty SA, a subsidiary of Glenmark Pharma, revealed a contract for exclusive marketing and distribution with BeiGene, a worldwide oncology firm. According to a statement from the business, Glenmark will be responsible for the registration and commercialization of BeiGene's oncology drugs, Tislelizumab and Zanubrutinib, in India. Tislelizumab is a newly developed monoclonal antibody that targets the PD-1 protein. It has been approved by the NMPA, EMA, and FDA for treating advanced or metastatic esophageal squamous cell carcinoma. Additionally, it is being extensively studied for its potential in treating different types of cancers. 


In March 2024, the FDA granted approval for tislelizumab-jsgr (Tevimbra) as a standalone treatment for patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) who have previously had systemic chemotherapy, excluding the use of a PD-L1 inhibitor. This information was provided in a press statement by BeiGene, the company responsible for developing the drug. Tislelizumab is expected to be commercially accessible in the United States during the latter part of 2024, as stated by the developers. The approval was granted after evaluating the outcomes of the phase 3 RATIONALE 302 study (NCT03430843), which compared the effectiveness of tislelizumab as a standalone treatment versus chemotherapy in the second-line treatment for this group of patients. 


Esophageal Squamous Cell Carcinoma Market Trends



  • The increasing prevalence of achalasia to boost the market growth.


The increasing prevalence of achalasia aid market growth because achalasia patients have a higher risk of Esophageal Squamous Cell Carcinoma than the general population. The journal Annals of Oesophagus reports that 9 to 10 people per 100,000 people experience achalasia each year.


Furthermore, achalasia can cause food retention, which can lead to bacterial overgrowth, irritation, and chronic inflammation, a pathophysiological process that has been proposed to lead to squamous cell carcinoma. Moreover, two recent meta-analyses found that the incidence rate of squamous cell carcinoma in patients with achalasia ranges from 1.36/1,000 patients-years to 3.12/1,000 patients-years, with risks of 1.5% and 2.8%, respectively.


Moreover, according to the International Agency for Research on Cancer, these rates are 15 and 34 times higher, respectively, than the risk of Esophageal Squamous Cell Carcinoma in the general population. Therefore, increasing prevalence of achalasia will directly affect the market growth of global Esophageal Squamous Cell Carcinoma positively.


Esophageal Squamous Cell Carcinoma Market Segment Insights


Esophageal Squamous Cell Carcinoma Diagnosis and Treatment Insights


The Market segments of Esophageal Squamous Cell Carcinoma, based on diagnosis and treatment, whereas, diagnosis is further segmented into Endoscopy, CT scan, Esophagram, Positron Emission Tomography (PET) and others. Likewise, treatment is further segregated into Surgery, Chemotherapy, Radiotherapy, Immunotherapy, And Others.


Treatment Segment dominated the market in 2022, while the diagnosis segment is projected to be the fastest-growing during the forecast period, 2023–2030 in the Esophageal Squamous Cell Carcinoma Market revenue. This is due to the increasing prevalence of cancer, introduction of new highly effective medications with lower secondary effects and rising demand for chemotherapy for the market's expansion.


June 2022: Eli Lilly and Company and Innovent Biologics, Inc. (China), a biopharmaceutical company, announced approval for TYVYT (sintilimab injection) for first line treatment for Esophageal Squamous Cell Carcinoma by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA).


Esophageal Squamous Cell Carcinoma End User Insights


The Esophageal Squamous Cell Carcinoma Market segmentation is based on end user which includes hospitals, specialty centers and others.


The hospital segment dominated the market in 2022. This is attributed to the rising prevalence of cancer further require drug discovery and development which fuels the market growth. While the specialty centers segment is projected to be the fastest–growing segment during the forecast period, 2022–2032.


Increased research & development also fuels the market growth of Esophageal Squamous Cell Carcinoma. For instance, according to the research done by Western Reserve University, U.S. in February 2019 found that the most prevalent esophageal cancer in the US, esophageal adenocarcinoma, could be reduced by blocking two molecular pathways that send signals inside cancer cells (EAC). This demonstrated the effectiveness of a novel therapeutic strategy for the treatment of esophageal cancer known as JNK/TGF-beta-targeted therapy.


Figure 2: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY MOLECULE TYPE, 2022 & 2032 (USD Billion)


ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY MOLECULE TYPE, 2022 & 2032


Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review


Esophageal Squamous Cell Carcinoma Regional Insights


By Region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. The North America Esophageal Squamous Cell Carcinoma market accounted for the largest market share in 2022. This is due to the rising prevalence of esophageal cancer which is raising the demand for the Esophageal Squamous Cell Carcinoma treatment market. Moreover, the increasing investment by major key players in better treatment alternatives is also expected to foster North America’s market growth.


Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.


Figure 3: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET SHARE BY REGION 2022 & 2032


ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET SHARE BY REGION 2022 & 2032


Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review


Europe Esophageal Squamous Cell Carcinoma market accounts for the second-largest market share due to the rising inclination towards smoke, tobacco, and drink is driving up demand for an advanced treatment option for Esophageal Squamous Cell Carcinoma. Moreover, rising healthcare expenditure is also expected to support the growth of the market. further, the Germany market of Esophageal Squamous Cell Carcinoma was attributed to hold the largest market share, and the Rest of Europe expected to fastest-grow during the forecast period.


The Asia-Pacific Esophageal Squamous Cell Carcinoma market is expected to grow at a significant share from 2023 to 2032. This is due to factors such as the rising incidence of Esophageal Squamous Cell Carcinoma, and the high population of tobacco smoking and alcohol drinking in this region is further expected to boost the market growth. Furthermore, the Increasing physical inactivity and poor lifestyle are also expected to boost the growth of the regional market. Moreover, China market of Esophageal Squamous Cell Carcinoma is expected to hold the largest market share, and Rest of Asia-Pacific market is expected fastest-growing region.


The Rest of the World is segmented into the Middle East, Africa, and Latin America. The market in the above-mentioned regions is likely to witness growth due to strong epidemiological factors, and improving healthcare facilities, increasing awareness about healthy lifestyles. Moreover, improving medical infrastructure in developing and underdeveloped countries, and growing inclination towards advanced treatment solution further drive the market growth of the Esophageal Squamous Cell Carcinoma in the regions clustered as Rest of the World.


Esophageal Squamous Cell Carcinoma Key Market Players & Competitive Insights


The Esophageal Squamous Cell Carcinoma Market is characterized by the presence of many global, regional, and local vendors catering to the demand created by research scientists and pharmaceutical and biotechnology companies operating in the industry. The market comprises tier-1, tier-2, and local players. The tier-1 and tier-2 players have reach across the globe with diverse product portfolios. Companies such as include Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (China) and Seagen Inc. (US) among others, dominate the Market of Esophageal Squamous Cell Carcinoma due to product differentiation, financial stability, strategic developments, and diversified regional presence. The players are focused on investing in research and development. Furthermore, they adopt strategic growth initiatives, such as expansion, product launches, joint ventures, and partnerships, to strengthen their market position and capture a large customer base.


One of the primary business strategies adopted by manufacturers in the global Esophageal Squamous Cell Carcinoma industry to benefit clients and expand the market of Esophageal Squamous Cell Carcinoma sector is to manufacture locally to reduce operating costs.



  • Hoffmann-La Roche Ltd (Roche) is one of the leading companies in the field of diagnostics and pharmaceuticals. It develops and markets products for the diagnosis & treatment of anemia, cancer, anticoagulation therapy, cardiovascular diseases, diabetes, central nervous system, chlamydia, dermatology, gonorrhea, gout, hepatitis B and C, hemostasis disorders, HIV/AIDS, HPV, infectious diseases, and autoimmune diseases. The company supplies in-vitro diagnostics and drugs for cancer and transplantation. Moreover, it specializes in the field of molecular diagnostics and medicines for oncology, virology, inflammation, metabolism, central nervous system (CNS), clinical chemistry, immunology, urinalysis, blood screening, genetics, infectious diseases, and microbiology. In addition, the company has offices and subsidiaries throughout the Americas, Europe, the Middle East, Africa, and Asia-Pacific.


Also, AstraZeneca is a leading biopharmaceutical company. It focuses on developing and commercializing prescribed medicines. It has three main therapy areas, namely, cardiovascular, and metabolic disease (CVMD), oncology, and respiratory. It is also active in areas such as neuroscience autoimmunity and infection. It has more than 164 projects in its pipeline, nine new molecular entities in its late-stage pipeline, and one new molecular entity approval in the last quarter of 2019. Its product portfolio includes medications in the field of oncology, cardiovascular, renal & metabolism, and respiratory diseases, among others. Geographically the company operates in more than 100 countries by offering its healthcare products to millions of people across the globe.


Key Companies in the market of Esophageal Squamous Cell Carcinoma include



  • Hoffmann-La Roche Ltd

  • AstraZeneca

  • Chia Tai Tianqing Pharmaceutical Group Co. Ltd.

  • Seagen Inc.

  • Eli Lilly and Company

  • Glaxosmithkline Plc

  • Novartis AG

  • Beijing Shenzhou Cell Biotechnology Group Co., Ltd.

  • Jacobio Pharmaceuticals Group Co., Ltd


Esophageal Squamous Cell Carcinoma Industry Developments


September 2021: The FDA has approved Seagen Inc’s TIVDAK (Tisotumab vedotin). It is used to treat cervical cancer that is recurrent or metastatic and Esophageal Squamous Cell Carcinoma cancer. It is also used in women whose cancer got worse during or after treatment with chemotherapy.


September 2022: The US FDA has approved AstraZeneca's Imfinzi plus in the US for patients with advanced biliary tract cancer, HCC, BTC, esophageal and gastric cancer.


Esophageal Squamous Cell Carcinoma Market Segmentation


Esophageal Squamous Cell Carcinoma Diagnosis and Treatment Outlook



  • Diagnosis

    • Endoscopy

    • CT Scan

    • Esophagram

    • Positron Emission Tomography (PET)

    • Others



  • Treatment

    • Surgery

    • Chemotherapy

    • Radiotherapy

    • Immunotherapy

    • Others




Esophageal Squamous Cell Carcinoma End User Outlook



  • Hospitals

  • Specialty Centres

  • Others


Esophageal Squamous Cell Carcinoma Regional Outlook



  • North America

    • US

    • Canada



  • Europe

    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Rest of Europe



  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific



  • Rest of the World

    • Middle East

    • Africa

    • Latin America



Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.